Literature DB >> 12612468

11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.

H Zhang1, M Tian, N Oriuchi, T Higuchi, H Watanabe, J Aoki, S Tanada, K Endo.   

Abstract

We assessed and compared the usefulness of C-choline positron emission tomography (PET) with that of 2-[ F]fluoro-2-deoxy-D-glucose (FDG) PET for the differentiation between benign and malignant bone and soft tissue tumours. A total of 43 patients with 45 lesions were included. C-choline PET and FDG PET were performed from 5 and 40 min, respectively, after injection of 275-370 MBq tracer. PET data were evaluated by using the standardized uptake value (SUV) and were analysed according to the pathological data. C-choline uptake in malignancies was 4.9+/-2.1 (n=14), which was significantly higher than that in benign lesions (2.5+/-1.7, n=31) (P <0.0001). The sensitivity, specificity and accuracy of C-choline PET were 100%, 64.5% and 75.6%, respectively, when 2.59 of the SUV was used as the cut-off value. The FDG uptake in malignancies was 5.1+/-4.2 (n=14) and was also significantly larger than that in benign lesions 2.9+/-2.9 (n=31) (P<0.003). The sensitivity, specificity and accuracy of FDG PET were 85.7%, 41.9% and 55.6%, respectively (cut-off=1.83). The C-choline uptake in the lesions correlated with FDG uptake ( r=0.61, P<0.003). In receiver operating characteristic (ROC) analysis, the area under the ROC curve for C-choline PET (area=0.847) was higher than that for FDG PET (area=0.717). This study showed that C-choline PET was superior to FDG PET in differentiation between malignant and benign lesion in bone and soft tissue tumours. C-choline PET might be useful as a screening method for malignant bone and soft tissue tumours.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12612468     DOI: 10.1097/00006231-200303000-00007

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  8 in total

1.  Intramuscular diffuse-type giant cell tumor within the hamstring muscle.

Authors:  Tatsuya Yoshida; Akio Sakamoto; Kazuhiro Tanaka; Yukihide Iwamoto; Yoshinao Oda; Teiyu Izumi; Masazumi Tsuneyoshi
Journal:  Skeletal Radiol       Date:  2006-07-19       Impact factor: 2.199

Review 2.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

3.  Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.

Authors:  Mei Tian; Hong Zhang; Noboru Oriuchi; Tetsuya Higuchi; Keigo Endo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-11       Impact factor: 9.236

4.  18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET.

Authors:  Matthias T Wyss; Bruno Weber; Michael Honer; Nicolas Späth; Simon M Ametamey; Gerrit Westera; Beata Bode; Achim H Kaim; Alfred Buck
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-20       Impact factor: 9.236

5.  Comparison of cell proliferation, protein, and glucose metabolism in musculoskeletal tumors in a PET study.

Authors:  Mei Tian; Hong Zhang; Keigo Endo
Journal:  J Biomed Biotechnol       Date:  2011-06-16

6.  Use of ¹¹C-Choline positron emission tomography/computed tomography to investigate the mechanism of choline metabolism in lung cancer.

Authors:  Zhaoqin Huang; Jun Rui; Xin Li; Xiangjiao Meng; Qingwei Liu
Journal:  Mol Med Rep       Date:  2015-01-14       Impact factor: 2.952

7.  Myxoid liposarcoma with negative features on bone scan and [18F]-2-fluoro-2-deoxy-D-glucose-positron emission tomography.

Authors:  Akio Sakamoto; Yoshiaki Fukutoku; Yoshihiro Matsumoto; Katsumi Harimaya; Yoshinao Oda; Yukihide Iwamoto
Journal:  World J Surg Oncol       Date:  2012-10-09       Impact factor: 2.754

8.  Epithelioid sarcoma with muscle metastasis detected by positron emission tomography.

Authors:  Akio Sakamoto; Osamu Jono; Minako Hirahashi; Masafumi Oya; Yukihide Iwamoto; Ken Arai
Journal:  World J Surg Oncol       Date:  2008-08-15       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.